Nesina (nes-SEE-na, alogliptin) will compete for your prescription in a crowded market of gliptins for type 2 diabetes
Nesina (nes-SEE-na, alogliptin) will compete for your prescription in a crowded market of gliptins for type 2 diabetes.
This new DPP-4 inhibitor is a "me too"...similar to Januvia (sitagliptin), Onglyza (saxagliptin), and Tradjenta (linagliptin).
Continue to recommend lifestyle changes and metformin first.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote